2D Pharmacophore Query Generation
Using pharmacophores in virtual screening of large chemical compound libraries proved to be a valuable concept in computer-aided drug design. Traditionally, pharmacophore-based screening is performed in 3D space where crystallized or predicted structures of ligands are superposed and where pharmacophore features are identified and compiled into a 3D pharmacophore model. However, in many cases the structures of the ligands are not known which results in using a 2D pharmacophore model.
We introduce a method capable of automatic generation of 2D pharmacophore models given previous knowledge about the biological target of interest. The knowledge comprises of a set of known active and inactive molecules with respect to the target. From the set of active and inactive molecules 2D pharmacophore features are extracted using pharmacophore fingerprints. Then a statistical procedure is applied to identify features separating the active from the inactive molecules and these features are then used to build a pharmacophore model. Finally, a similarity measure utilizing the model is applied for virtual screening.
The method was tested on multiple state of the art datasets and compared to several virtual screening methods. Our approach seems to exceed the existing methods in most cases. We believe that the presented methodology forms a valuable addition to the set of tools available for the early stage drug discovery process.
Keywords2D pharmacophores pharmacophore modeling virtual screening
Unable to display preview. Download preview PDF.
- 1.RDKit, http://www.rdkit.org/ (accessed: April 15, 2014)
- 4.Ehrlich, P.: Über den jetzigen Stand der Chemotherapie. Verlag der Chemiker-Zeitung Otto v. Halem (1908)Google Scholar
- 5.Ferreira, R.S., Simeonov, A., Jadhav, A., Eidam, O., Mott, B.T., Keiser, M.J., McKerrow, J.H., Maloney, D.J., Irwin, J.J., Shoichet, B.K.: Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. J. Med. Chem. 53(13), 4891–4905 (2010)CrossRefGoogle Scholar
- 7.Gaulton, A., Bellis, L.J., Bento, A.P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., Overington, J.P.: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Research 40(D1), D1100–D1107 (2011)Google Scholar
- 9.Hert, J., Willett, P., Wilton, D.J., Acklin, P., Azzaoui, K., Jacoby, E., Schuffenhauer, A.: Comparison of fingerprint-based methods for virtual screening using multiple bioactive reference structures. Journal of Chemical Information and Computer Sciences 44(3), 1177–1185 (2004)Google Scholar
- 12.Chemical Computing Group Inc.: Molecular Operating Environment (MOE), 2013.08 (2013)Google Scholar
- 14.Johnson, M.A., Maggiora, G.M.: Concepts and Applications of Molecular Similarity. Wiley-Interscience (1990)Google Scholar
- 17.McGregor, M.J., Pallai, P.V.: Clustering of large databases of compounds: using the mdl keys as structural descriptors. Journal of Chemical Information and Computer Sciences 37(3), 443–448 (1997)Google Scholar
- 18.R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria (2008) ISBN 3-900051-07-0Google Scholar
- 26.Tanimoto, T.: IBM Internal Report 17th November (1957)Google Scholar
- 28.Wang, Y., Xiao, J., Suzek, T.O., Zhang, J., Wang, J., Bryant, S.H.: Pubchem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Research 37(Web-Server-Issue), 623–633 (2009)Google Scholar